[Iressa for refractory XXXX : A preliminary report].

@entity1 @entity1665 @entity137 @entity390 @entity1910 @entity9645 @entity5 @entity294 @entity1149 @entity3 @entity1054
BACKGROUND: To summarize the preliminary experience on Iressa for refractory @entity1149 ( @entity1149 ). METHODS: Fifty-five @entity1 with @entity1149 , who failed after surgery, radiotherapy, chemotherapy or combination of the above modalities, were registered in this clinical trail. Prior to Iressa, 50 @entity1 were in stage IV, and 5 in stage III. Iressa was administered orally at 250 mg, once a day until @entity5 progressed or severe @entity137 occured, which made @entity1 intolerable. The median time for administration of Iressa was 4 months. RESULTS: The @entity137 of Iressa was tolerable with 47% of @entity137 ( @entity1910 ) and 2%-7% of @entity294 , @entity390 , @entity9645 and @entity1665 . Overall response rate was 20%. Different sites of distant metastases responded to Iressa in different ways with higher response rate for pulmonary disseminations. One quarter of @entity1 felt improvement of their symptoms over 2 weeks. Median survival time for entire group was 5 months (1-17 months). Median @entity1054 ( @entity1054 ) was 3.6 months. Survival at 6 months was 67%. Prognostic predictor, which could imply the outcome, was @entity137 with higher response rate and longer survival time ( P < 0.05), and no relationship with sex, histological types of @entity1149 and distant @entity3 had been found. CONCLUSIONS: Iressa could be tolerated by refractory @entity1149 @entity1 with acceptable side-effects, and have palliative effects.
